Vu Dang Luu, Pham Minh Thong, Nguyen Van Bang, Le Thi My
Bach Mai Radiology Center, Bach Mai Hospital, Hanoi, Vietnam.
Center of Endocrinology and Diabetes, Family Hospital, Da Nang, Vietnam.
Ther Clin Risk Manag. 2022 Jan 6;18:11-19. doi: 10.2147/TCRM.S344464. eCollection 2022.
This study aims to evaluate the efficacy and safety of RFA in the AFTN treatment after 2 years of follow-up and to find the factors related to treatment responses through TSH level and VRR.
This long-term prospective study was conducted from September 2017 to April 2021 on 17 AFTNs treated with RFA. Clinical evaluations, thyroid function tests, thyroid scintigraphy, and ultrasonography examinations were performed at 1 month, 3 months, 6 months, and 24 months after ablation. The primary endpoint was the success rate of RFA in restoring the euthyroidism stage after 24 months of follow-ups; secondary outcomes were VRR and improvements of US parameters, clinical examinations, and complications. The Spearman rank correlation test was used to determine related factors with treatment response variables.
At the 24 months after the procedure, symptom score, cosmetic score, vascularity grade, and nodule volume significantly decreased. The VRR reduced approximately 42.77%, 63.13%, 78.3%, and 95.65% after 1 month, 3 months, 6 months, and 24 months follow-up. All 17 patients were restored euthyroid state without taking ATDs. No major complications were collected. The last TSH level was significantly correlated with the age of patients (Spearman rho = -0.637, p = 0.008). The VRR was significantly correlated with age of patients (Spearman rho = 0.566, p = 0.018) and initial TSH (Spearman rho = 0.485, p = 0.048).
RFA was demonstrated as a safe and effective option for AFTN treatment in long-term follow-up. It can be used as an alternative treatment with encouraging results.
本研究旨在通过2年的随访评估射频消融术(RFA)治疗自主功能性甲状腺结节(AFTN)的疗效和安全性,并通过促甲状腺激素(TSH)水平和体积缩小率(VRR)找出与治疗反应相关的因素。
本长期前瞻性研究于2017年9月至2021年4月对17例接受RFA治疗的AFTN患者进行。在消融后1个月、3个月、6个月和24个月进行临床评估、甲状腺功能测试、甲状腺闪烁扫描和超声检查。主要终点是随访24个月后RFA恢复甲状腺功能正常阶段的成功率;次要结果是VRR以及超声参数、临床检查和并发症的改善情况。采用Spearman等级相关检验确定与治疗反应变量相关的因素。
术后24个月时,症状评分、美容评分、血管分级和结节体积显著降低。随访1个月、3个月、6个月和24个月后,VRR分别降低约42.77%、63.13%、78.3%和95.65%。所有17例患者均恢复甲状腺功能正常状态,无需服用抗甲状腺药物(ATD)。未收集到重大并发症。末次TSH水平与患者年龄显著相关(Spearman相关系数ρ=-0.637,p=0.008)。VRR与患者年龄(Spearman相关系数ρ=0.566,p=0.018)和初始TSH(Spearman相关系数ρ=0.485,p=0.048)显著相关。
在长期随访中,RFA被证明是治疗AFTN的一种安全有效的选择。它可作为一种替代治疗方法,效果令人鼓舞。